PDCD1 and melanoma: Clinical data indicated that PD1 and T cell Ig and ITIM domain (TIGIT) inhibitors regulated the expansion and function of tumor antigen-specific CD8+ T cell in melanoma patients [94], indicating that combining multiple checkpoint inhibitors could be a viable approach to prevent T cell exhaustion.